Stock Watch: Where Novo And Lilly Lead, Others Follow
AstraZeneca Resurrects Its Metabolic Franchise
AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.
You may also be interested in...
From the unfavorable comparisons brought about by lower pandemic-related product sales, vaccines for other diseases bring hopes for longer-term success.
CEO Pascal Soriot fielded questions on a wide range of topics – from China to US Medicare drug price negotiations – at a media briefing in New York City.
The SELECT cardiovascular outcomes trial is a convincing hit; now Novo Nordisk must grapple with reimbursement and manufacturing.